In lung adenocarcinoma, CCT3 knockdown resensitised cancer cells to cisplatin by inhibiting the Janus kinase 2 (JAK2)/STAT3 pathway143 (Figure 6). Here, JAK2 is linked to lung adenocarcinoma.